Weijian Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weijian Zhu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Jiangming Chen
Department of Haematology, Wuzhou Gongren Hospital, Wuzhou, 543001, People’s Republic of China
2 shared publications- Bin Lin
Guangzhou Huayin Healthcare Group Co ., Ltd., Guangzhou 510663
1 shared publication - Binbin Huang
Department 1 of Internal Medicine, Sixth People’s Hospital of Nanning , Nanning 530022
1 shared publication - Caiyun Li
Center of Prenatal Diagnosis, Chenzhou No.1 People’s Hospital , Chenzhou 423000
1 shared publication - Chao Niu
Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, Guangdong, China, China
1 shared publication - Chengwu Fan
Department of pediatrics, Second People’s Hospital of Guilin , Guilin 541001
1 shared publication
Latest Publications
- Open Access
- 27 September 2024
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Whole-genome Sequencing Association Analysis of Quantitative Platelet Traits in A Large Cohort of β-thalassemia
Platelet acts as a crucial monitoring indicator for hypercoagulability and thrombosis and a key target for drug regulation. Genotype–phenotype association studies have confirmed that platelet traits are quantitatively regulated by multiple genes. However, there is currently a lack of genetic studies on the heterogeneity of platelet traits in β-thalassemia under hypercoagulable state. Here, we studied the phenotypic heterogeneity of platelet count (PLT) and mean platelet volume (MPV) in 1020 β-thalassemia patients. We further performed a functionally informed whole genome sequencing association analysis of common variants and rare variants (RVs) for PLT and MPV in 916 patients through integrative analysis of whole-genome sequencing data and functional annotation data. Extreme phenotypic heterogeneity of platelet traits was observed in β-thalassemia patients. Additionally, the common variant based gene-level analysis identified the novel gene of RNF144B associated with MPV. The RV analysis identified several novel associations in both coding and noncoding genome, including missense RVs of PPP2R5C associated with PLT and missense RVs of TSSK1B associated with MPV. In conclusion, we performed a comprehensive and systematic whole genome scan of platelet traits in the β-thalassemia cohort, demonstrating the specificity of genetic regulation of platelet traits in the context of β-thalassemia, providing potential targets for intervention.
- 27 September 2024
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Open AccessWhole-genome Sequencing Association Analysis of Quantitative Platelet Traits in A Large Cohort of β-thalassemia
Platelet acts as a crucial monitoring indicator for hypercoagulability and thrombosis and a key target for drug regulation. Genotype–phenotype association studies have confirmed that platelet traits are quantitatively regulated by multiple genes. However, there is currently a lack of genetic studies on the heterogeneity of platelet traits in β-thalassemia under hypercoagulable state. Here, we studied the phenotypic heterogeneity of platelet count (PLT) and mean platelet volume (MPV) in 1020 β-thalassemia patients. We further performed a functionally informed whole genome sequencing association analysis of common variants and rare variants (RVs) for PLT and MPV in 916 patients through integrative analysis of whole-genome sequencing data and functional annotation data. Extreme phenotypic heterogeneity of platelet traits was observed in β-thalassemia patients. Additionally, the common variant based gene-level analysis identified the novel gene of RNF144B associated with MPV. The RV analysis identified several novel associations in both coding and noncoding genome, including missense RVs of PPP2R5C associated with PLT and missense RVs of TSSK1B associated with MPV. In conclusion, we performed a comprehensive and systematic whole genome scan of platelet traits in the β-thalassemia cohort, demonstrating the specificity of genetic regulation of platelet traits in the context of β-thalassemia, providing potential targets for intervention.
- Open Access
- 1 April 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1729-1738
Long-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience
Objective: We evaluated the long-term safety and efficacy of thalidomide in the treatment of transfusion-dependent β-thalassemia (TDT). Methods: Fifty patients with TDT were treated with thalidomide and followed-up for 5 years. Thalidomide at a 50 mg dose was administered once a day after dinner. The dose was increased to 150 mg/d after 3 d if well tolerated. After 1 year of treatment, the hemoglobin (Hb) level was stabilized at its maximum, and thalidomide was gradually reduced and maintained at the minimum dose. The hematological response, transfusion dependence, and haemolytic indicators were assessed. Results: At 9 month of follow-up, 38 (76%) patients achieved an excellent response, 1 (2%) a good response, 4(8%) a minor response, and 7(14%) did not show a response. The overall response rate was 86%. At 9 months, the Hb level increased from 79.0 ± 13.2 g/L at baseline to 99.0 ± 13.7g/L (P< 0.001). Patients who achieved excellent response continued to show an increase in Hb levels during follow-up. At 48 months, the mean Hb level was 98.99 ± 10.3g/L; 21 patients (84.0%) became transfusion independent. Thalidomide was reduced and maintained to 25 mg/d in three of these patients. Moreover, five patients completed 60 months of follow-up, and with a mean Hb level of 99.8 ± 6.7g/L. During follow-up, grade 1– 2 adverse drug reactions were noted; however, no grade 3 or higher adverse event was reported. However, no decrease in hemolytic indicators was observed. Conclusion: Thalidomide was well tolerated in the long term, while it significantly improved Hb levels and reduced the transfusion burden.
- 1 April 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1729-1738
Open AccessLong-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience
Objective: We evaluated the long-term safety and efficacy of thalidomide in the treatment of transfusion-dependent β-thalassemia (TDT). Methods: Fifty patients with TDT were treated with thalidomide and followed-up for 5 years. Thalidomide at a 50 mg dose was administered once a day after dinner. The dose was increased to 150 mg/d after 3 d if well tolerated. After 1 year of treatment, the hemoglobin (Hb) level was stabilized at its maximum, and thalidomide was gradually reduced and maintained at the minimum dose. The hematological response, transfusion dependence, and haemolytic indicators were assessed. Results: At 9 month of follow-up, 38 (76%) patients achieved an excellent response, 1 (2%) a good response, 4(8%) a minor response, and 7(14%) did not show a response. The overall response rate was 86%. At 9 months, the Hb level increased from 79.0 ± 13.2 g/L at baseline to 99.0 ± 13.7g/L (P< 0.001). Patients who achieved excellent response continued to show an increase in Hb levels during follow-up. At 48 months, the mean Hb level was 98.99 ± 10.3g/L; 21 patients (84.0%) became transfusion independent. Thalidomide was reduced and maintained to 25 mg/d in three of these patients. Moreover, five patients completed 60 months of follow-up, and with a mean Hb level of 99.8 ± 6.7g/L. During follow-up, grade 1– 2 adverse drug reactions were noted; however, no grade 3 or higher adverse event was reported. However, no decrease in hemolytic indicators was observed. Conclusion: Thalidomide was well tolerated in the long term, while it significantly improved Hb levels and reduced the transfusion burden.
- 27 September 2017
- Published by Wiley in European Journal of Haematology
- Vol. 99 (5) , 437-441
Thalidomide induces haematologic responses in patients with β‐thalassaemia
Objective: This study aimed to evaluate the clinical and laboratory outcomes of a group of patients with β‐thalassaemia major or intermedia treated with thalidomide.Methods: Clinical and laboratory data were obtained by analysing medical records of β‐thalassaemia patients. Using the self‐control method, the levels of haemoglobin (Hb), foetal haemoglobin (HbF), white blood cells (WBC) and platelets were detected before and after the treatment, and adverse reactions were recorded.Results: Data from the medical records of 9 patients were analysed. The median haemoglobin levels of these patients increased from 5.13 ± 2.15 g/dL before treatment to 10.38 ± 1.19 g/dL after treatment. The average spleen size decreased from a pretreatment length of 8.19 ± 3.10 to 5.49 ± 1.80 cm below the costal margin after treatment. The mean HbF levels increased from a pretreatment value of 35.67% ± 26.82% to 75.67% ± 14.64% after treatment in the 9 patients for whom these measurements were available. All patients no longer needed transfusions by 1 month after treatment. No serious adverse reactions were observed in any of the thalidomide‐treated patients.Conclusion: In this study, thalidomide showed an outstanding effect on β‐thalassaemia patients who required frequent red‐cell transfusions. Thalidomide increased haemoglobin levels without causing serious adverse reactions, but the long‐term curative outcomes and other side effects should be observed continuously.
- 27 September 2017
- Published by Wiley in European Journal of Haematology
- Vol. 99 (5) , 437-441
Thalidomide induces haematologic responses in patients with β‐thalassaemia
Objective: This study aimed to evaluate the clinical and laboratory outcomes of a group of patients with β‐thalassaemia major or intermedia treated with thalidomide.Methods: Clinical and laboratory data were obtained by analysing medical records of β‐thalassaemia patients. Using the self‐control method, the levels of haemoglobin (Hb), foetal haemoglobin (HbF), white blood cells (WBC) and platelets were detected before and after the treatment, and adverse reactions were recorded.Results: Data from the medical records of 9 patients were analysed. The median haemoglobin levels of these patients increased from 5.13 ± 2.15 g/dL before treatment to 10.38 ± 1.19 g/dL after treatment. The average spleen size decreased from a pretreatment length of 8.19 ± 3.10 to 5.49 ± 1.80 cm below the costal margin after treatment. The mean HbF levels increased from a pretreatment value of 35.67% ± 26.82% to 75.67% ± 14.64% after treatment in the 9 patients for whom these measurements were available. All patients no longer needed transfusions by 1 month after treatment. No serious adverse reactions were observed in any of the thalidomide‐treated patients.Conclusion: In this study, thalidomide showed an outstanding effect on β‐thalassaemia patients who required frequent red‐cell transfusions. Thalidomide increased haemoglobin levels without causing serious adverse reactions, but the long‐term curative outcomes and other side effects should be observed continuously.
- Open Access
- 2 February 2010
- Published by Wiley in Brain Pathology
- Vol. 20 (2) , 503-506
A 25‐YEAR‐OLD WOMAN WITH A MASS IN THE HIPPOCAMPUS
Angiocentric gliomas (AG) have only recently been described. We encountered a 25-year-old woman with AG who had a history of epilepsy for two years. MRI revealed that there was a solid tumor in the hippocampus. The tumor was totally removed. Histologically, the spindle tumor cells proliferated around small parenchymal vessels with perivascular pseudorosettes. The tumor cells of the hippocampus surface umbilicated forming rosettes. Immunohistochemistry demonstrated positivity for GFAP, Vimentin and S-100, but were negative for neurofilament protein, Syn, CgA and P53. EMA had "dot-like" positive staining. The proliferation index was less than 1%. The location of the tumor and the pathological findings confirm that the diagnose was AG. Epilepsy disappeared after the operation. When fully resected these tumors have a good prognosis.
- 2 February 2010
- Published by Wiley in Brain Pathology
- Vol. 20 (2) , 503-506
Open AccessA 25‐YEAR‐OLD WOMAN WITH A MASS IN THE HIPPOCAMPUS
Angiocentric gliomas (AG) have only recently been described. We encountered a 25-year-old woman with AG who had a history of epilepsy for two years. MRI revealed that there was a solid tumor in the hippocampus. The tumor was totally removed. Histologically, the spindle tumor cells proliferated around small parenchymal vessels with perivascular pseudorosettes. The tumor cells of the hippocampus surface umbilicated forming rosettes. Immunohistochemistry demonstrated positivity for GFAP, Vimentin and S-100, but were negative for neurofilament protein, Syn, CgA and P53. EMA had "dot-like" positive staining. The proliferation index was less than 1%. The location of the tumor and the pathological findings confirm that the diagnose was AG. Epilepsy disappeared after the operation. When fully resected these tumors have a good prognosis.